Inventor · disambiguated record
Rangaprasad Sarangarajan
Also filed as: SARANGARAJAN RANGAPRASAD
27 granted patents·40 pending applications·74 citations·filing 2010–2024
95Inventor score
Top patents by PatentIndex Score
67 records- 0194US9205064B2Methods for the diagnosis of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencersNARAIN NIVEN RAJIN·Filed 2010·Granted Dec 8, 2015·18 cites·14 claims
- 0292US10519504B2Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencersNARAIN NIVEN RAJIN·Filed 2010·Granted Dec 31, 2019·11 cites·23 claims
- 0389US10376477B2Method of treating or preventing tumors of the central nervous systemBERG LLC·Filed 2016·Granted Aug 13, 2019·6 cites·24 claims
- 0489US9901542B2Methods of treatment of cancer by continuous infusion of coenzyme Q10BERG LLC·Filed 2014·Granted Feb 27, 2018·10 cites·53 claims
- 0586US2024161863A1Interrogatory cell-based assays for identifying drug-induced toxicity markersBERG LLC·Filed 2024·Application pending·0 cites
- 0685US11456054B2Interrogatory cell-based assays and uses thereofBERG LLC·Filed 2018·Granted Sep 27, 2022·2 cites·27 claims
- 0784US11298313B2Methods of treatment of cancer by continuous infusion of coenzyme Q10BERG LLC·Filed 2018·Granted Apr 12, 2022·1 cites·36 claims
- 0883US10933032B2Methods for the treatment of cancer using coenzyme Q10 combination therapiesBERG LLC·Filed 2014·Granted Mar 2, 2021·3 cites·32 claims
- 0983US2025123283A1Use of markers including filamin a in the diagnosis and treatment of prostate cancerBERG LLC·Filed 2024·Application pending·0 cites
- 1082US10539566B2Use of markers including filamin A in the diagnosis and treatment of prostate cancerBERG LLC·Filed 2015·Granted Jan 21, 2020·3 cites·23 claims
- 1181US2024062844A1Interrogatory cell-based assays and uses thereofBPGBIO INC·Filed 2023·Application pending·0 cites
- 1280US9886545B2Interrogatory cell-based assays and uses thereofNARAIN NIVEN RAJIN·Filed 2012·Granted Feb 6, 2018·4 cites·22 claims
- 1378US10352947B2Use of markers in the identification of cardiotoxic agents and in the diagnosis and monitoring of cardiomyopathy and cardiovascular diseaseBERG LLC·Filed 2013·Granted Jul 16, 2019·3 cites·14 claims
- 1476US10061887B2Interrogatory cell-based assays and uses thereofVISHNUDAS VIVEK K·Filed 2012·Granted Aug 28, 2018·6 cites·27 claims
- 1576US2021002725A1Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencesBERG LLC·Filed 2020·Application pending·0 cites
- 1676US2021332439A1Methods for the diagnosis of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencersBERG LLC·Filed 2020·Application pending·0 cites
- 1774US11452699B2Method of treating or preventing tumors of the central nervous systemBERG LLC·Filed 2019·Granted Sep 27, 2022·0 cites·27 claims
- 1873US9533002B2Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-βNARAIN NIVEN RAJIN·Filed 2013·Granted Jan 3, 2017·2 cites·32 claims
- 1973US9360454B2Methods and kits for detection of coenzyme Q10BERG LLC·Filed 2013·Granted Jun 7, 2016·2 cites·82 claims
- 2073US2023285272A1Methods of treatment of cancer by continuous infusion of coenzyme q10BPGBIO INC·Filed 2022·Application pending·0 cites
- 2172US12303471B2Methods of treatment of temozolomide-resistant glioma using coenzyme Q10BPGBIO INC·Filed 2022·Granted May 20, 2025·0 cites·21 claims
- 2271US2023302022A1Preventing or mitigating chemotherapy induced alopecia using vitamin dBERG LLC·Filed 2022·Application pending·0 cites
- 2370US11224641B2Enolase 1 (ENO1) compositions and uses thereofBERG LLC·Filed 2018·Granted Jan 18, 2022·0 cites·16 claims
- 2470US2020333344A1Use of markers including filamin a in the diagnosis and treatment of prostate cancerBERG LLC·Filed 2019·Application pending·0 cites
- 2569US10188708B2Enolase 1 (Eno1) compositions and uses thereofBERG LLC·Filed 2015·Granted Jan 29, 2019·1 cites·18 claims
- 2669US2019010554A1Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencesBERG LLC·Filed 2017·Application pending·0 cites
- 2768US11694765B2Interrogatory cell-based assays for identifying drug-induced toxicity markersBERG LLC·Filed 2018·Granted Jul 4, 2023·0 cites·17 claims
- 2868US10188707B2Enolase 1 (Eno1) compositions and uses thereofBERG LLC·Filed 2015·Granted Jan 29, 2019·1 cites·26 claims
- 2968US2025120927A1Cndp2 modulators and methods for their useMETABOLON INC·Filed 2024·Application pending·0 cites
- 3068US2018334721A1Methods for the diagnosis of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencersNARAIN NIVEN RAJIN·Filed 2017·Application pending·0 cites
- 3168US2023142060A1Coenzyme q10 formulations in the treatment and prevention of epidermolysis bullosaBERG LLC·Filed 2022·Application pending·0 cites
- 3266US11419830B2Use of coenzyme Q10 formulations in the treatment and prevention of epidermolysis bullosaBERG LLC·Filed 2018·Granted Aug 23, 2022·0 cites·17 claims
- 3366US2022107322A1Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancerBERG LLC·Filed 2021·Application pending·0 cites
- 3464US10114013B2Method for detection of coenzyme Q10BERG LLC·Filed 2016·Granted Oct 30, 2018·1 cites·13 claims
- 3563US9797905B2Use of markers in the diagnosis and treatment of prostate cancerBERG LLC·Filed 2016·Granted Oct 24, 2017·0 cites·33 claims
- 3663US2018031563A1Use of markers in the diagnosis and treatment of prostate cancerBERG LLC·Filed 2017·Application pending·0 cites
- 3763US2017137879A1Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencersBERG LLC·Filed 2016·Application pending·0 cites
- 3863US2021369645A1Methods for the treatment of cancer using coenzyme q10 combination therapiesBERG LLC·Filed 2021·Application pending·0 cites
- 3963US2016145693A1Methods for the diagnosis of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencersBERG LLC·Filed 2015·Application pending·0 cites
- 4062US2021322339A1Combination therapy of coenzyme q10 and radiation for treatment of gliomaBERG LLC·Filed 2020·Application pending·0 cites
- 4161US12320812B2Markers for the diagnosis of biochemical recurrence in prostate cancerBPGBIO INC·Filed 2020·Granted Jun 3, 2025·0 cites·7 claims
- 4261US11209422B2Methods and kits for detection of coenzyme Q10BERG LLC·Filed 2018·Granted Dec 28, 2021·0 cites·14 claims
- 4360US12437835B2Interrogatory cell-based assays and uses thereofBERG LLC·Filed 2018·Granted Oct 7, 2025·0 cites·43 claims
- 4460US2022096400A1Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulatorsBERG LLC·Filed 2021·Application pending·0 cites
- 4560US2021169999A1Enolase 1 (eno1) compositions and uses thereofBERG LLC·Filed 2020·Application pending·0 cites
- 4659US2014038838A1Use of markers in the diagnosis and treatment of prostate cancerNARAIN NIVEN RAJIN·Filed 2013·Application pending·0 cites
- 4757US2022064732A1Methods for treating parkinson's diseaseBERG LLC·Filed 2021·Application pending·0 cites
- 4856US11001891B2Methods for treating Parkinson's diseaseBERG LLC·Filed 2017·Granted May 11, 2021·0 cites·16 claims
- 4956US2025079000A1Methods and markers for diagnosis of parkinson's diseaseBERG LLC·Filed 2022·Application pending·0 cites
- 5055US2023059578A1Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancerBERG LLC·Filed 2022·Application pending·0 cites
Showing the top 50 of 67 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Rangaprasad Sarangarajan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →